Introduction
Prostate cancer is the most prevalent malignancy diagnosed in males and the second leading cause of cancer-related mortality in the United States and Europe (1, 2) .
There is currently no effective therapy for advanced cancer progression. Epidemiologic evidence is mounting for a close relationship between dietary high-fat intake and prostate carcinogenesis and lethal progression (3) (4) (5) . Accumulated experimental research also suggests that activation of de novo lipogenesis (6) (7) (8) and cholesterogenesis (9-11) induces prostate cancer cell proliferation and promotes cancer development and progression.
Therefore, pharmacological intervention blocking fatty acid and cholesterol anabolisms could potentially be a novel therapy for malignant prostate cancer.
Sterol regulatory element-binding proteins (SREBPs) are basic helix-loop-helix leucine (bHLH) zipper transcription factors that transcriptionally activate genes involved in fatty acid and cholesterol biosynthesis and homeostasis (12, 13) . Precursor SREBPs are synthesized as endoplasmic reticulum (ER) membrane-bound forms. Through sequentially proteolytic cleavage by site-1 (S1P) and site-2 (S2P) proteases, the Nterminus of SREBPs translocate into the nucleus and trigger the expression of target genes having sterol regulatory elements (SRE), cis-acting elements in their 5'-flanking promoter regions (13, 14) . Three isoforms of SREBPs have been identified including SREBP-1a, SREBP-1c and SREBP-2 (13, 15) . SREBP-1a mainly regulates genes associated with fatty acid and cholesterol biosynthesis (12, 13) . SREBP-2 is particularly involved in the transcriptional control of cholesterol anabolism (16) . Overexpression of SREBP-1 has been found in human prostate cancer tissues and LNCaP xenograft tumor tissues during androgen refractory/castration-resistant progression (17, 18) . Additionally, our recent data showed that SREBP-1 and its nuclear form were highly elevated in clinical prostate cancer specimens with aggressive pathologic features compared to nontumor prostate tissues (18) . Furthermore, SREBP-1 promoted cell viability and castration-resistant progression via alterations of lipogenesis, oxidative stress and androgen receptor (AR) expression in prostate cancer cells (18) . Previous reports revealed that SREBP-2 activity was increased in prostate cancer cells and targeting this activity altered cell membrane cholesterol content and inhibited signaling transduction mediated by cholesterol-rich lipid rafts (11, 17, (19) (20) (21) . These discoveries provide a rationale for blocking SREBPs and their controlling metabolic and signaling pathways by pharmacological intervention as a potential approach for prostate cancer therapy.
Fatostatin, a non-sterol diarylthiazole derivative, was originally developed from a chemical library to inhibit insulin-induced adipogenesis (22) and decreased the amounts of fatty acid, triglyceride and low-density lipoprotein and reduce body weight by perturbing the nuclear translocation of SREBP in obese mice with low cytotoxicity (23) .
Fatostatin has been shown to have the potential efficacy in glioma cells (24) . Here, we report that fatostatin is a novel anti-prostate tumor agent that suppresses cell proliferation, tumorigenesis and progression and induces apoptotic death in prostate cancer cells in vitro and in vivo by blocking SREBP activation and inhibiting fatty acid and cholesterol biosynthesis as well as AR signaling. This study indicates that inhibition of SREBP could be exploited as a promising therapy against malignant prostate cancer. 
Materials and Methods

Cell lines and culture conditions
The human prostate cancer LNCaP cell line and C4-2B, a LNCaP linage-derived bone metastatic subline were kindly provided by Dr. Leland W.K. Chung in December 2010 (25) . Mouse embryo fibroblast NIH-3T3 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA) in November 2013. These cell lines have not been further authenticated. LNCaP and C4-2B cells were cultured in T-Medium (Life Technologies). NIH-3T3 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Life Technologies). All cell lines were grown in medium with 10% FBS (Atlanta biologicals), 100 IU/mL of penicillin and 100 µg/mL of streptomycin in a humidified atmosphere of 5% CO 2 at 37 o C.
Compounds and reagents
Fatostatin
(4-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-2-propylpyridine hydrobromide) was purchased from Chembridge Corporation and its chemical structure was described in Supplementary Fig. S1 . 
Cell prolifeation, clonogencity, invasion and migration assays
Prostate cancer cells were seeded on 96-well plates in triplicate and treated with vehicle or fatostatin for 72 hours. Cell proliferation was determined by MTS assay (Promega) according to the manufacturer's instructions. For the growth curve assay, cells were seeded on 24-well plates and treated with vehicle or fatostatin (2.5, 5 or 10 µmol/L) for 5 days. Cell numbers from triplicate wells were counted. For the clonogenic assay, cells were suspended in culture medium containing 0.3% agarose (FMC BioProducts) with vehicle or fatostatin, and placed on top of solidified 0.6% agarose in 6-well plates.
The developed colonies were counted and recorded under a microscope after 3-week incubation. In vitro cell invasion or migration was determined in Boyden chambers precoated with growth factor reduced BD Matrigel matrix (invasion assay) or collagen I (migration assay) as cells as previously described (18) . After incubation for 48 hours, invading or migrating cells were photographed and counted to calculate the relative cell invasion and migration.
Quantitative real-time RT-PCR (qRT-PCR) analysis
Total RNA from each sample was isolated by RNeasy mini Kit (Qiagen). Firststrand cDNA was synthesized from total RNA (1 μg) using SuperScript III reverse transcriptase (Life Technologies) with random hexamer primers. qPCR was performed on ABI 7500 Fast Real-Time PCR System using the SYBR Green PCR Master mix from Table S1 .
Western blot Analysis
Cell lysates were prepared from prostate cancer cells as previously described (26) and Western blot was performed using Mini-PROTEAN system (Bio-Rad). Primary were stained by Oil Red O working solution and were examined by a phase contrast microscope (18) .
Quantification of fatty acid and total cholesterol
The amounts of fatty acid and cholesterol were measured using Free Fatty Acid Quantification Kit and Cholesterol/Cholesterol Ester Detection Kit according to the manufacturer's instructions (Abcam) in cells treated with vehicle or fatostatin (21) . Assay Kit (Promega) and normalized to β-Galactosidase luciferase activity by cotransfection of β-Galactosidase control vector. pSRE-Luc, SREBP-1 (OriGene Technologies), SREBP-2, CMV500 A-SREBP1 and CMV500 A-SREBP2 (Addgene) vectors were transfected into cells as described above.
Cell cycle and apoptosis analysis
Mouse xenograft experiments
All animal experiments were performed in accordance with the protocol approved by the Cedars-Sinai Medical Center Institution Animal Care and Use Committee.
Athymic nu/nu male mice (4-week-old, Taconic) were implanted subcutaneously with C4-2B cells (1 × 10 6 ). Tumor burdens were monitored by calipers and calculated using the formula: V = 1/2 × length × width 
Statistical Analysis
All quantitative results are expressed as means ± SD. Statistically significant differences were obtained using a 2-tailed Student's t test. A value of P < 0.05 was considered to be statistically significant in all experiments. To further define the mechanism underlying fatostatin-induced apoptotic cell death, we first examined a number of well-defined apoptotic markers involving caspase-3/7 enzymatic activity in prostate cancer cells by luminescence cleavage of specific substrates (Promega). A marked increase of caspase-3/7 enzymatic activities was found in LNCaP and C4-2B cells exposed to fatostatin with a dose-dependent manner (Fig. 2C) .
Next, we determined the expression patterns of caspases by Western blot analysis.
Fatstatin decreased the expression of full-length caspases and increased the expression of cleaved caspase-9, -3 and PARP, a downstream factor of caspases, in LNCaP and C4-2B cells (Fig. 2D ). This indicates that fatostatin activates the apoptotic cascade pathway in (Fig. 3A) .
To confirm that fatostatin acts on the SREBP pathways, the transcriptional ability of SREBP was determined by the promoter-luciferase (Luc) and mutant constructs assays 
for several SREBP-regulated genes. As shown in Fig. 3C , fatostatin significantly decreased the activities of the pHMGCoASyn-Luc, pFASN-700-Luc and pLDLR-Luc reporters, but not that of the mutant pFASN-700-mutSRE and pLDLR-mutSRE reporters.
Moreover, the dominant negative SREBP forms (A-SREBP1 and A-SREBP2) were utilized to prove the specific effect of fatostatin on SREBP activation. Fatostatin significantly decreased the SRE-Luc activity in the presence of SREBP-1 or -2 expression vector but didn't affect the SRE-Luc activity in the presence of dominant negative forms (Supplementary Fig. S3 ). The results indicated that fatostatin specifically blocked SREBP activation and processing.
Since fatostatin inhibited key genes related to lipogenesis and cholesterogenesis through SREBPs, we subsequently performed staining and quantification assays to (Fig. 3D) . Additionally, fatostatin significantly decreased the levels of intracellular fatty acid compared to vehicle-treated cells (Fig. 3E) . The filipin fluorescent staining demonstrated that cholesterol accumulation was decreased in fatostatin-treated cells compared to vehicle-treated prostate cancer cells (Fig. 3F) . To further validate the results of the filipin fluorescent staining, we assayed the intracellular cholesterol levels in both cells. When LNCaP and C4-2B cells were exposed to fatostatin, total cholesterol amounts were significantly lower than vehicle-treated cells (Fig. 3G ).
These data suggest that inhibition of SREBPs by fatostatin caused a decrease in the levels of fatty acid and cholesterol in prostate cancer cells. 
Fatostain exhibits anti-tumor efficacy in a subcutaneous C4-2B xenograft mouse model
In view of the potent in vitro effect of fatostatin against prostate cancer cells ( Fig.   1 and 2) , we next examined the efficacy of fatostatin on human prostate cancer growth in immunodeficient mice. The volumes of subcutaneous C4-2 tumors treated with fatostatin were significantly smaller than those in the vehicle-treated control group over 42 days of observation (Fig. 4A) . Moreover, at the end of the animal experiment, the average weight of the excised tumors collected from the fatostatin group was greatly decreased to 18% of the control group (Fig. 4B) . Serum PSA levels of C4-2B tumor-bearing mice with fatostatin treatment were lower compared to control mice (Fig. 4C) . Additionally, the toxicity profile of fatostatin seemed quite favorable as body weight was not significantly affected by treatment with fatostatin compared to controls (Fig. 4D) .
Next, we examined the proliferation (Ki67) and apoptosis (cleaved PARP) in C4-2B tumor tissues by IHC staining. Consistent with the potent anti-tumor effects, the results showed that the fatostatin-treated tumors exhibited a significant decrease in a proliferative index (Ki67 status) compared to the vehicle-treated group (Fig. 4E) . A significant increase in cleaved PARP staining was observed in the fatostatin-treated tumors compared to the control tumors (Fig. 4E) . The in vivo data suggest that the predominant effect of fatostatin on subcutaneous C4-2B tumors is inhibition of proliferation and induction of apoptosis. 
Fatostatin decreases expression of AR and its target gene PSA in prostate cancer in vitro and in vivo
AR activity is essential for prostate cancer development, growth and castrationresistant progression. We previously showed that SREBP-1 transcriptionally induced AR expression and activity in prostate cancer cells (18) . Here, we tested the idea that 
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C4-2B cells (Fig. 6A) . We also observed that fatostatin blocked AR nuclear translocation in both cell lines (Supplementary Fig. S4 ). Furthermore, the results of Western blot analysis at different time points showed that fatostatin firstly inhibited the nuclear translocation of SREBP-1 and -2 (at 6 hours) and subsequently decreased AR expression (at 12 hours) in LNCaP and C4-2B cells (Fig. 6B) . It indicates that SREBPs are main targets of fatostatin but not AR. Consistent with the in vitro results, fatostatin inhibited the expression of both AR and PSA compared to the vehicle group as determined by Western blot (Fig. 6C ) and IHC staining (Fig. 6D ) in a C4-2B tumor xenograft mouse model. Additionally, the serum PSA levels of the fatostatin-treated mice were significantly reduced compared to the vehicle control group (Fig. 4C) . These in vitro and in vivo results suggest that this specific SREBP inhibitor inhibited AR expression and function in prostate cancer. 
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decreasing SREBP-1 transcriptional activity, since SREBP-1 has been demonstrated to transcriptionally mediate expression of these three lipogenic genes (12) . The data suggest that fatostatin decreased expression of cancer-associated lipogenic genes and further reduced intracellular fatty acid, to inhibit prostate cancer growth in vitro and in vivo.
Cholesterol is one of major components of lipid rafts, specialized microdomains of the plasma membrane that serve as organizing centers for the assembly of signaling molecules (41) . Therefore, rapidly proliferating cancer cells with highly activated signal transduction networks, such as prostate cancer cells, are likely to have an enhanced requirement for cholesterol (42) . Besides, cholesterol is a metabolic precursor for biosynthesis of steroid hormones, including androgens. SREBP-2 is a master transcription regulator that up-regulates several key cholesterogenic genes, such as HMGCS1, HMGCR and LDLR. HMGCR activity was increased in ex vivo LNCaP tumors during progression to a castration-resistant state in xenograft mouse models (43, 44) . Expression of LDLR has been demonstrated to be elevated in prostate cancer cells compared to normal cells, which could be due to the lack of sterol feedback regulation controlled by SREBP-2 in prostate cancer cells (45) . Blocking the intracellular cholesterol supply through inhibition of the LDLR pathway induced tumor cell death in vivo (46) . Our results showed that inhibition of SREBP-2 activity by fatostatin suppressed expression of these cholesterogenic genes and significantly reduced the levels of intracellular cholesterol in prostate cancer in vitro and in vivo, which is an essential component and precursor for the lipid raft-mediated survival signaling pathways and intracrine androgen biosynthesis. These results suggest that interrupting the SREBP-2 regulated cholesterogenic pathway may offer an attractive anti-prostate cancer approach. 
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Androgens exert their effects by interacting with AR to release heat shock proteins and allowing nuclear localization and DNA interaction. AR, a critical transcription, growth and survival factor, plays a key role in regulation of androgenresponsive organs during normal development and maintenance as well as prostate cancer growth and lethal hormone refectory/castration-resistant progression (47, 48) . The AR signaling axis provides a promising targeted therapy for prostate cancer malignancy.
Different strategies have been successfully attempted to target AR directly through gene transcription or translation or blocking the interaction between AR and its co-factors and their downstream functions in prostate cancer cells (26, 49) . We previously reported that SREBP-1 mediated AR transcriptional expression and activity by a mechanism of binding the AR promoter region in prostate cancer cells (18) . Additionally, knockingdown SREBP-1 led to decreases in AR mRNA and protein expression and inhibited prostate cancer cell viability (18, 27) . Furthermore, unpublished results showed that In summary, we uncovered the underlying molecular mechanisms by which fatostatin suppresses prostate cancer growth and tumorigenicity (Fig. 7) . Fatostatin was shown to inhibit cell proliferation, anchorage-independent colony formation and for 48 h, the levels of fatty acid in LNCaP and C4-2B cell were determined by Oil Red O staining and fatty acid quantification kit. *, P < 0.05, significant differences from vehicle treatment, scale bar = 100 μm. F-G, after 48 h incubation, fatostatin decreased the levels of cholesterols in LNCaP and C4-2B cells determined by filipin staining and cholesterol quantitation kit. *, P < 0.05 and **, P < 0.01 significant differences from vehicle group, scale bar =100 μm. 
